---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-042319"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:42:14.540293+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa Q4 net income $13.4M; Ph1 MRT-6160 >90% VAV1 deg, MRT-2359 CRPC response

## Summary
- Q4 2024 net income $13.4M vs net loss $33.3M in Q4 2023; collaboration revenue $60.6M from Novartis/Roche deals.
- Cash, equivalents, securities $377M as of Dec 31, 2024; expected to fund operations into 2028.
- MRT-6160 Phase 1 showed >90% VAV1 degradation, favorable safety; path to Phase 2 with Novartis.
- MRT-2359 in CRPC: confirmed partial response (-57%) in 1 of 3 evaluable patients; focus on CRPC moving forward.
- MRT-8102 NEK7 degrader on track for IND H1 2025; GLP tox showed >200-fold safety margin.

## SEC filing metadata
- accession: 0000950170-25-042319
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017025042319/0000950170-25-042319-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017025042319/glue-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-042319
- JSON: https://secwatch.observer/filing/0000950170-25-042319.json
- Plain text: https://secwatch.observer/filing/0000950170-25-042319.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.